BioCardia Inc
NASDAQ:BCDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Soho Development SA
WSE:SHD
|
PL |
|
Endurance Gold Corp
XTSX:EDG
|
CA |
|
Corporate Travel Management Ltd
ASX:CTD
|
AU |
|
S
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IST:SANEL.E
|
TR |
|
F
|
Fluoguide AS
STO:FLUO
|
DK |
|
Corbion NV
OTC:CSNVY
|
NL |
|
MP Materials Corp
NYSE:MP
|
US |
|
S
|
Symphony Life Bhd
KLSE:SYMLIFE
|
MY |
|
Siltronic AG
XETRA:WAF
|
DE |
|
Byke Hospitality Ltd
NSE:BYKE
|
IN |
BioCardia Inc
Research & Development
BioCardia Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCardia Inc
NASDAQ:BCDA
|
Research & Development
-$5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-13%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
BioCardia Inc
Glance View
BioCardia, Inc. operates as a clinical-stage regenerative medicine company. The company is headquartered in Sunnyvale, California and currently employs 28 full-time employees. The company is focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Its lead therapeutic candidates are based on the CardiAMP Cell Therapy System, a platform which provides an autologous bone marrow-derived cell therapy for treatment in two clinical indications, such as ischemic heart failure and refractory angina resulting from chronic myocardial ischemia. Its second therapeutic platform is an investigational bone marrow derived allogeneic off-the shelf Neurokinin-1 Receptor Positive mesenchymal stem cell (MSC) therapy for the treatment of cardiac and pulmonary disease. The company has three enabling device product lines: the CardiAMP cell processing system, the Helix biotherapeutic delivery system (Helix), and the Morph vascular access product line (Morph). The company is advancing therapeutic candidates for heart failure, chronic myocardial infarction, and acute respiratory distress syndrome.
See Also
What is BioCardia Inc's Research & Development?
Research & Development
-5m
USD
Based on the financial report for Dec 31, 2025, BioCardia Inc's Research & Development amounts to -5m USD.
What is BioCardia Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-13%
Over the last year, the Research & Development growth was -13%. The average annual Research & Development growth rates for BioCardia Inc have been 17% over the past three years , 13% over the past five years , and -13% over the past ten years .
